P
Piero Periti
Researcher at University of Florence
Publications - 84
Citations - 1985
Piero Periti is an academic researcher from University of Florence. The author has contributed to research in topics: Cefotetan & Pharmacokinetics. The author has an hindex of 22, co-authored 84 publications receiving 1909 citations.
Papers
More filters
Journal ArticleDOI
Pharmacokinetic Drug Interactions of Macrolides
TL;DR: These incriminated macrolide antibiotics should not be administered concomitantly with other drugs known to be affected metabolically by them, or at the very least, combined administration should be carried out only with careful patient monitoring.
Journal ArticleDOI
Clinical Pharmacokinetics of Depot Leuprorelin
TL;DR: Regular or depot leuprorelin treatment is well tolerated, and local reactions are more common after application of the 3- or 4- month depot in comparison with the 1-month depot.
Journal ArticleDOI
Adverse effects of macrolide antibacterials.
TL;DR: Physicians should be alerted to the possibility of unusual toxicity that could also emerge in the future from the new and recently developed macrolide antibacterials, coinciding with their expanded clinical use worldwide.
Journal Article
Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.
Giuseppe Pizzorno,Enrico Mini,Marcella Coronnello,John J. McGuire,B. A. Moroson,Arlene R. Cashmore,Robert N. Dreyer,James T. Lin,Teresita Mazzei,Piero Periti,Joseph R. Bertino +10 more
TL;DR: This is the first example of a cell line which displays resistance which is solely attributable to defective methotrexate polyglutamate synthesis, and the development of resistance to metotrexate was associated with a marked decrease in the intracellular level of methotRexate polyGLutamates.
Journal ArticleDOI
Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).
TL;DR: The pharmacokinetic aspects in humans of macrolide antibiotics that are currently or soon to be on the market, and the newer semisynthetic derivatives, such as roxithromycin, possess an antibacterial spectrum at least equivalent to that of erythromycin and other macrolides, allowing longer intervals between doses.